Scarica l'app Stockscreener
13.25
2.16%
0.28
Dopo l'orario di chiusura:
13.30
0.05
+0.38%
Precedente Chiudi:
$12.97
Aprire:
$13.03
Volume 24 ore:
1.15M
Relative Volume:
4.08
Capitalizzazione di mercato:
$494.70M
Reddito:
$50.00M
Utile/perdita netta:
$-59.98M
Rapporto P/E:
-6.068
EPS:
-2.1836
Flusso di cassa netto:
$-55.54M
1 W Prestazione:
+3.60%
1M Prestazione:
+1.92%
6M Prestazione:
+7.55%
1 anno Prestazione:
+222.38%
Intervallo 1D:
$12.90
$13.46
Intervallo di 1 settimana:
$12.56
$13.46
Portata 52W:
$3.35
$16.33
Contineum Therapeutics Inc Stock (CTNM) Company Profile
Nome
Contineum Therapeutics Inc
Settore
Industria
Telefono
(858) 333-5280
Indirizzo
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
Compare CTNM vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
13.25 | 484.25M | 50.00M | -59.98M | -55.54M | -2.1836 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-13 | Iniziato | Leerink Partners | Outperform |
| 2025-09-25 | Iniziato | Leerink Partners | Outperform |
| 2025-06-20 | Iniziato | William Blair | Outperform |
| 2024-10-22 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-30 | Iniziato | Morgan Stanley | Overweight |
| 2024-04-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-04-30 | Iniziato | Stifel | Buy |
Mostra tutto
Contineum Therapeutics Inc Borsa (CTNM) Ultime notizie
Bank Watch: Can Contineum Therapeutics Inc stock outperform in a bear marketWeekly Trade Analysis & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Contineum Therapeutics CSO sells $56k in CTNM stock - Investing.com UK
Pre-planned stock sale by Contineum (CTNM) chief scientific officer - Stock Titan
Daniel Lorrain sells via 10b5-1; CTNM (NASDAQ: CTNM) Form 144 notice - Stock Titan
CTNM Technical Analysis & Stock Price Forecast - Intellectia AI
Contineum (CTNM) Q2 R&D Jumps 78% - aol.com
MACD Signal: Can Contineum Therapeutics Inc stock outperform in a bear market2026 Volume & Low Volatility Stock Recommendations - baoquankhu1.vn
Guidance Update: Is Contineum Therapeutics Inc currently under institutional pressure2026 Opening Moves & Stepwise Trade Signal Guides - baoquankhu1.vn
Sentiment Review: Is Contineum Therapeutics Inc currently under institutional pressureWeekly Investment Summary & Real-Time Market Sentiment Alerts - baoquankhu1.vn
We Think Contineum Therapeutics (NASDAQ:CTNM) Can Afford To Drive Business Growth - 富途牛牛
Companies Like Contineum Therapeutics (NASDAQ:CTNM) Are In A Position To Invest In Growth - simplywall.st
Retail Trends: What is the Moat Score of Contineum Therapeutics Inc2026 Pullbacks & Low Risk Entry Point Guides - baoquankhu1.vn
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Contineum Therapeutics (NASDAQ:CTNM) Trading 8.7% HigherStill a Buy? - MarketBeat
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Bond Watch: Will Corvus Pharmaceuticals Inc stock go up in YEAR2026 Levels & Daily Entry Point Trade Alerts - baoquankhu1.vn
Contineum Therapeutics, Inc.Common stock (NQ: CTNM - The Chronicle-Journal
Revenue Check: Is FKWL still a buy after recent gainsStock Surge & Detailed Earnings Play Alerts - baoquankhu1.vn
Contineum Therapeutics Highlights PIPE-791 IPF Trial, J&J-Backed PIPE-307 Catalysts at Leerink Conference - Defense World
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 13, 2026 - BioSpace
Contineum Therapeutics, Inc. $CTNM Shares Sold by Baker BROS. Advisors LP - MarketBeat
Baird Maintains Contineum Therapeutics (CTNM) Outperform Recommendation - MSN
Certain Options of Contineum Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 12-MAR-2026. - marketscreener.com
6,083,338 Class B common stock of Contineum Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 12-MAR-2026. - marketscreener.com
Contineum’s MS drug falls short in Phase II trial - MSN
Update Recap: How sensitive is Contineum Therapeutics Inc to inflationQuarterly Profit Review & Daily Chart Pattern Signals - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX), Contineum Therapeutics, Inc. Class A (CTNM) and Aktis Oncology, Inc. (AKTS) - The Globe and Mail
Contineum Therapeutics, Inc. (CTNM) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Contineum Therapeutics, Inc. Class A Common Stock share price - Mint
Can Contineum Therapeutics Inc. stock resist sector downturns2026 Institutional & Risk Adjusted Buy and Sell Alerts - Naître et grandir
Contineum Therapeutics (NASDAQ:CTNM) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
RBC Capital Remains a Buy on Contineum Therapeutics, Inc. Class A (CTNM) - The Globe and Mail
Contineum Therapeutics (NASDAQ:CTNM) Price Target Raised to $20.00 at Robert W. Baird - MarketBeat
Contineum Therapeutics Expands ATM Facility, Highlights Pipeline Progress - The Globe and Mail
Stifel reiterates Buy on Contineum stock, keeps $29 price target By Investing.com - Investing.com South Africa
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Developme - PharmiWeb.com
Stifel reiterates Buy on Contineum stock, keeps $29 price target - Investing.com India
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones - The National Law Review
Contineum Therapeutics (NASDAQ:CTNM) Posts Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Contineum reports Q4 EPS (49c), consensus (39c) - TipRanks
Contineum Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Contineum Therapeutics Q4 Earnings Summary & Key Takeaways - Benzinga
CTNM: Phase 2 IPF trial dosing started, $93M raised, and cash runway extends into mid-2029 - TradingView
Contineum Therapeutics (NASDAQ: CTNM) posts Q4 loss, adds $100,000,000 at-the-market stock capacity - Stock Titan
CTNM SEC FilingsContineum Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
According to the latest public documents from the U.S. Securities and Exchange Commission (SEC), biopharmaceutical company Contineum Therapeutics Inc. has launched a new stock offering plan. - Bitget
USD News Center - University of San Diego
Contineum Therapeutics Faces Downgrade Following Clinical Trial Setback () - aktiencheck.de
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference - Business Wire
CTNMContineum Therapeutics Latest Stock News & Market Updates - Stock Titan
Contineum Therapeutics to Present at September Investor Conferences - Business Wire
Contineum Therapeutics Inc Azioni (CTNM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):